Slotnik Capital LLC Reduces Stock Position in Inhibrx Biosciences, Inc. $INBX

Key Points

• Slotnik Capital LLC reduced its stake in Inhibrx Biosciences by 26.0%, selling 101,038 shares to hold 286,962 shares, making it the firm's 11th largest position.
• Inhibrx reported a quarterly EPS of ($1.85), surpassing analyst expectations of ($2.92), and had revenues of $1.30 million for the quarter.
• Currently, 82.46% of Inhibrx Biosciences' stock is owned by institutional investors and hedge funds, indicating significant institutional interest.

Slotnik Capital LLC cut its position in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) by 26.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 286,962 shares of the company's stock after selling 101,038 shares during the period. Inhibrx Biosciences makes up 1.9% of Slotnik Capital LLC's holdings, making the stock its 11th largest position. Slotnik Capital LLC owned approximately 1.98% of Inhibrx Biosciences worth $4,015,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of INBX. Wells Fargo & Company MN purchased a new stake in shares of Inhibrx Biosciences in the 4th quarter valued at $102,000. Barclays PLC acquired a new position in Inhibrx Biosciences during the fourth quarter valued at $289,000. Northern Trust Corp purchased a new stake in Inhibrx Biosciences in the fourth quarter valued at $1,788,000. Jane Street Group LLC purchased a new stake in Inhibrx Biosciences in the fourth quarter valued at $1,362,000. Finally, BNP Paribas Financial Markets acquired a new stake in Inhibrx Biosciences during the 4th quarter worth about $128,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Inhibrx Biosciences Price Performance

NASDAQ:INBX opened at $29.10 on Tuesday. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 1.45. Inhibrx Biosciences, Inc. has a 52 week low of $10.81 and a 52 week high of $29.39. The stock's 50-day moving average price is $23.12 and its 200-day moving average price is $16.63. The stock has a market capitalization of $421.37 million, a PE ratio of -2.75 and a beta of 0.31.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($1.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.92) by $1.07. The business had revenue of $1.30 million for the quarter. As a group, equities analysts expect that Inhibrx Biosciences, Inc. will post 104.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. JMP Securities restated a "market perform" rating on shares of Inhibrx Biosciences in a research note on Friday, August 22nd. Wall Street Zen raised Inhibrx Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has a consensus rating of "Hold".

About Inhibrx Biosciences

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.